Metcela is a clinical-stage Kanagawa-based biotech company bringing cell-based therapies to heart failure patients.
Sector: Life Sciences
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform.
J-Pharma
J-Pharma is a clinical stage biopharmaceutical company with a mission to create and develop novel pharmaceuticals. J-Pharma is conducting trials in Japan for advanced stage cancer patients. Learn more at j-pharma.com.
REDPINE
REDPINE is a medical technology company that provides complete solutions for medical business. It focuses on the research and development and production of single-use Class III medical devices, initially endoscopes for urology and gynecology.
Sironax
Sironax is a developer of pharmaceuticals for inflammatory and neuro-degenerative diseases. The company researches apoptosis and other cell death pathways to develop quality pharmaceuticals, enabling healthcare professionals to prescribe advanced treatments to their patients.
Skyline Therapeutics
Skyline Therapeutics (formerly Geneception) is a fully-integrated gene and cell therapy based in Hangzhou and Shanghai, China. Founded by F-Prime Capital, Eight Roads Ventures China and Lilly Asia Ventures in 2018, Skyline’s mission is to become a preeminent gene and cell therapy company, working to deliver world-class therapeutics for patients in China and globally.
LenoMed
LenoMed is a company that develops and produces insulin pumps.
Harlan Krumholz, MD
Harlan Krumholz joined F-Prime in August 2020 as a Venture Partner and is focused on transformative approaches to improve the delivery of care, conduct of research, and empowerment of people in their health decisions – and measures success by the positive, tangible effect on people’s lives. He believes in medicine as an information science and wants to advance approaches that make health care more effective, patient-centric, precise, convenient, equitable, efficient, and to position health care to be smarter with every interaction. He is the Harold H. Hines, Jr. Professor of Medicine at Yale University and the founding Director of the Yale New Haven Hospital Center for Outcomes Research and Evaluation, one of the nation’s first and most distinguished groups focusing on using applied science to improve health and healthcare. He is also a founder of two companies and an advisor for many others.
Harlan received his BS from Yale College, his MD from Harvard Medical School, and an SM from the Harvard School of Public Health.
RareStone
RareStone (formerly Citrine Medicine) is a rare disease-focused therapeutics company focused on the Greater China market that was co-founded by Eight Roads Ventures, F-Prime Capital and Vivo Capital. RareStone is dedicated to improving the lives of rare disease patients by making diagnosis and essential treatments available and accessible for those who need them.
Rallybio
Rallybio (NASDAQ: RLYB) is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders.